Friederike Schumann

Statistics

Publications

Citations

157

H-Index

Active since

2018

Affiliations

Charité - Universitätsmedizin Berlin(Current)

Christian-Albrechts-Universität zu Kiel

Inserm

University of Rostock

University Hospital Heidelberg

Friederike Schumann is an author at Charité - Universitätsmedizin Berlin specializing in cardiovascular pharmacotherapy, pcsk9 inhibitors, and pcsk9 inhibitor therapy.

ORCID

Publications per year

2018–2025

Publications

High interindividual variability in LDL-cholesterol reductions after inclisiran administration in a real-world multicenter setting in Germany

Umidakhon Makhmudova, Ulrike Schatz, Nikolaos Perakakis et al. · Clinical Research in Cardiology · 2023 · 49 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

The size of apolipoprotein (a) is an independent determinant of the reduction in lipoprotein (a) induced by PCSK9 inhibitors

Valentin Blanchard, Kévin Chemello, Tim Hollstein et al. · Cardiovascular Research · 2021 · 30 citations

Life Sciences, Biochemistry, Pharmacology +15

PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular Risk Over 68 Weeks

Tim Hollstein, Ursula Kassner, Thomas Grenkowitz et al. · American Journal of Cardiovascular Drugs · 2020 · 23 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

The interrelations between PCSK9 metabolism and cholesterol synthesis and absorption

Günther Silbernagel, Lars K. Steiner, Tim Hollstein et al. · Journal of Lipid Research · 2018 · 20 citations · Full text

Life Sciences, Pharmacology, Pharmacotherapy +17

Treatment with PCSK9 inhibitors induces a more anti-atherogenic HDL lipid profile in patients at high cardiovascular risk

Cécile Ingueneau, Tim Hollstein, Thomas Grenkowitz et al. · Vascular Pharmacology · 2020 · 13 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +16

1–5 of 7